Forest Laboratories, Inc.
) will now enjoy an additional six months of exclusivity in the
U.S. for its Alzheimer's disease drug, Namenda (memantine
hydrochloride). This covers both Namenda IR and Namenda XR.
Forest Labs has settlement agreements with quite a few generic
companies regarding the launch of generic versions of Namenda IR.
Under these agreements, these companies are entitled to launch
their generic versions of Namenda IR three months before U.S.
Patent No. 5,061,703 expires including any extensions and/or
pediatric exclusivities. With the '703 patent scheduled to expire
on Apr 11, 2015, generics were earlier expected to enter the market
in Jan 2015. However, now that pediatric exclusivity has been
obtained, generics can enter the market in Jul 2015.
Forest Labs is exploring all avenues to extend the Namenda
franchise's life-cycle. The company is currently switching patients
on Namenda IR to Namenda XR, which was launched in Jun 2013.
Namenda XR, a 28mg once-daily, extended-release formulation of
Namenda IR, delivered sales of $135.8 million in fiscal 2014.
Meanwhile, Forest Labs along with partner,
), is currently seeking FDA approval for a fixed dosed combination
of Namenda XR and Aricept for the once-daily treatment of moderate
to severe dementia of the Alzheimer's type. The plan is to launch
this combination (provided FDA approval is gained) before the entry
of generic versions of Namenda IR in 2015. The pediatric
exclusivity provides the company with more time to execute its
plans for the extension of the Namenda life cycle.
Forest Labs is a Zacks Rank #2 (Buy) stock. The company has an
) under which Actavis will acquire Forest Labs for about $25
billion (cash and equity). The acquisition is expected to close
A better-ranked stock in the health care sector is
), a Zacks Rank #1 (Strong Buy) stock.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
FOREST LABS A (FRX): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
ACTAVIS PLC (ACT): Free Stock Analysis Report
ADAMAS PHARMA (ADMS): Free Stock Analysis
To read this article on Zacks.com click here.